Bio-outsourcing

Pic:getty/markrubens

WuXi Biologics to build CRDMO center in Singapore

By Rachel Arthur

CDMO WuXi Biologics will invest $1.4bn in a 10 year investment plan to expand its research, development, and large-scale drug substance and drug product manufacturing capacity and capabilities in Singapore.

© GettyImages/Atstock Productions

SGS acquires live biotherapeutics focused CDMO

By Jane Byrne

SGS, the Swiss-based testing, inspection and certification company, has acquired Quay Pharma, a UK based pharmaceutical industry targeted contract development and manufacturing organization (CDMO).

Follow us

Product Innovations